Clot lysis time and thrombin activatable fibrinolysis inhibitor in severe preeclampsia with or without associated antiphospholipid antibodies

Journal of Reproductive Immunology

Volumn 86, Issue 2, 2010, Pages 133-140

  Martínez Zamora, M Angeles ^a   Tassies, Dolors ^a   Carmona, Francisco ^a   Espinosa, Gerard ^a   Cervera, Ricard ^a   Reverter, Juan Carlos ^a   Balasch, Juan ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antiphospholipid antibodies; Antiphospholipid syndrome; Clot lysis time; Preeclampsia; Pregnancy; Thrombin activatable fibrinolysis inhibitor

Indexed keywords

PHOSPHOLIPID ANTIBODY; THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR;

ADULT; ALLELE; ARTICLE; BLOOD CLOT LYSIS; CONTROLLED STUDY; DELIVERY; DISEASE SEVERITY; DNA POLYMORPHISM; FEMALE; HUMAN; MAJOR CLINICAL STUDY; PREECLAMPSIA; PREGNANCY; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE; THIRD TRIMESTER PREGNANCY;

ADULT; ALLELES; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; BLOOD COAGULATION TESTS; CARBOXYPEPTIDASE U; FEMALE; FIBRINOLYSIS; HUMANS; POLYMORPHISM, GENETIC; POSTPARTUM PERIOD; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY TRIMESTERS; RISK FACTORS;

EID: 77957252571     PISSN: 01650378     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jri.2010.05.002     Document Type: Article

References (44)

1. Ajjan R.A., Standeven K.F., Khanbhai M., Phoenix F., Gersh K.C., Weisel J.W., et al. Effects of aspirin on clot lysis structure and fibrinolysis using a novel in vitro cellular system. Arterioscler. Thromb. Vasc. Biol. 2009, 29:712-717.
2. Akatsu H., Yamagata H., Chen Y., Miki T., Kamino K., Takeda M. TAFI polymorphisms at amino acids 147 and 325 are not risk factors for cerebral infarction. Br. J. Haematol. 2004, 127:440-447.
3. Alacacioglu I., Ozcan M.A., Alacacioglu A., Polat M., Yuksel F., Demirkan F., et al. Plasma levels of thrombin activatable fibrinolysis inhibitor in normal and preeclamptic pregnant women. Thromb. Res. 2004, 114:155-159.
4. Alfirevic Z., Roberts D., Martlew V. How strong is the association between maternal thrombophilia and adverse pregnancy outcome? A systematic review. Eur. J. Obstet. Gynecol. Reprod. Biol. 2002, 101:6-14.
5. American College of Obstetrics and Gynecology ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. No. 33, January 2002. Obstet. Gynecol. Obstet. 2002, 99:159-167.
6. American College of Obstetrics and Gynecology ACOG practice bulletin. Perinatal care at the threshold of viability. No. 38, September 2002. Int. J. Gynaecol. Obstet. 2002, 79:181-188.
7. Antovic J.P., Rafik Hamad R., Antovic A., Blomback M., Bremme K. Does thrombin activatable fibrinolysis inhibitor (TAFI) contribute to impairment of fibrinolysis in patients with preeclampsia and/or intrauterine fetal growth retardation?. Thromb. Haemost. 2002, 88:644-647.
8. Balasch J., Carmona F., Creus M., Font J., Cervera R. Management of reproductive failure in the antiphospholipid syndrome. The Antiphospholipid Syndrome II: Autoimmune Thrombosis 2002, 375-394. Elsevier Science B.V., Amsterdam. R.A. Asherson, R. Cervera, R.-C. Piette, Y. Schoenfeld (Eds.).
9. Bjornsson T.D., Schneider D.E., Berger H. Aspirin acetylates fibrinogen and enhances fibrinolysis. Fibrinolytic effect is independent of changes in plasminogen activator levels. J. Pharmacol. Exp. Ther. 1989, 250:154-161.
10. Bouma B.N., Meijers J.C. Thrombin-activatable fibrinolysis inhibitor (TAFI, plasma procarboxypeptidase B, procarboxypeptidase R, procarboxypectidase U). J. Thromb. Haemost. 2003, 1:1566-1574.
11. Branch D.W., Silver R., Blackwell J., Reading J., Scott J.R. Outcome of treated pregnancies in women with antiphospholipid syndrome: an update of the Utah experience. Obstet. Gynecol. 1992, 80:614-620.
12. Brandt J.T., Triplett D.A., Alving B., Scharrer I. Criteria the diagnosis of lupus anticoagulant: an update. Subcommittee on Lupus Anticoagulant/Antiphospholipid Antibody of the Scientific and Standardisation Committee of the ISTH. Thromb. Haemost. 1995, 74:1185-1190.
13. Brouwers G.J., Vos H.L., Leebeek F.W.G., Bulk S., Schneide R.M., Boffa M. A novel, possibly functional, single nucleotide polymorphism in the coding region of the thrombin-activatable fibrinolysis inhibitor (TAFI) gene is also associated with TAFI levels. Blood 2001, 98:1193-1992.
14. Carmona F., Font J., Azulay M., Creus M., Fabregues F., Cervera R., et al. Risk factors associated with fetal losses in treated antiphospholipid syndrome pregnancies: a multivariate analysis. Am. J. Reprod. Immunol. 2001, 46:274-279.
15. Carmona F., Lazaro I., Reverter J.C., Taséis D., Font J., Cervera R., et al. Impaired factor XIIa-dependent activation of fibrinolysis in treated antiphospholipid syndrome gestations developing late-pregnancy complications. Am. J. Obstet. Gynecol. 2006, 194:457-465.
16. Cellai A.P., Antonucci E., Liotta A.A., Fedi S., Marcucci R., Falciani M. TAFI activity and antigen plasma levels are not increased in acute coronary artery disease patients admitted to a coronary care unit. Thromb. Res. 2006, 118:494-500.
17. Chabloz P., Reber G., Boehlen F., Hohlfeld P., De Moerloose P. TAFI antigen and D-dimer levels during normal pregnancy and at delivery. Br. J. Haematol. 2001, 115:150-152.
18. Chetaille P., Alessi M.C., Morange P.E., Juhan-Vague I. Plasma TAFI antigen variations in healthy subjects. Thromb. Haemost. 2000, 83:902-905.
19. Colucci M., Pentimone A., Binetti B.M., Cramarossa M., Piro D., Semeraro N. Effect of heparin on TAFI-dependent inhibition of fibrinolysis: relative importance of TAFIa generated by clot-bound and fluid phase thrombin. Thromb. Haemost. 2002, 88:282-287.
20. Curnow J.L., Morel-Kopp M.-C., Roddie C., Aboud M., Ward C.M. Reduced fibrinolysis and increased fibrin generation can be detected in hypercoagulable patients using the overall hemostatic potential assay. J. Thromb. Haemost. 2006, 5:528-534.
21. De Maat M.P.M., Jansen M.W.J.C., Hille E.T.M., Vos H.L., Bloemerkamp K.W.M., Buitendkijk S., et al. Preeclampsia and its interaction with common variants in thrombophilia genes. J. Thromb. Haemost. 2004, 2:1588-1593.
22. Eichinger S., Schönauer V., Weltermann A., Minar E., Bialonczyk C., Hirschl M. Thrombin-activatable fibrinolysis inhibitor and the risk for recurrent venous thromboembolism. Blood 2004, 103:3773-3776.
23. Espinosa G., Cervera R., Font J., Shoenfeld Y. Antiphospholipid syndrome: pathogenic mechanisms. Autoimmun. Rev. 2003, 2:86-93.
24. Forastiero R., Martinuzzo M. Prothrombotic mechanisms based on the impairment of fibrinolysis in the antiphospholipid syndrome. Lupus 2008, 17:872-877.
25. Franco R.F., Fagundes M.G., Meijers J.C., Meijers J.C., Reitsma P.H., Lourenço D., Morelli V. Identification of polymorphisms in the 5'-untranslated region of the tafi gene: relationship with plasma TAFI levels and risk of venous thrombosis. Haematologica 2001, 86:510-517.
26. Gils A., Alessi M.C., Browers E., Peeters M., Marx P., Leurs J., et al. Development of a genotype 325-specific proCPU/TAFI ELISA. Arterioscler. Thromb. Vasc. Biol. 2003, 23:1122-1127.
27. Goldenberg N.A., Hathaway W.E., Jacobson L., Manco-Johnson M.J. A new global assay of coagulation and fibrinolysis. Thromb. Res. 2005, 116:345-356.
28. Henry M., Aubert H., Morange P.E., Nanni I., Alessi M.C., Tiret L., et al. Identification of polymorphisms in the promoter and the 3' region of the TAFI gene: evidence that plasma TAFI antigen levels are strongly genetically controlled. Blood 2001, 97:2053-2058.
29. Lisman T., Leebek F.W.G., Meijer K., Van Der Meer J., Nieuwenhuis K., De Groot P. Recombinant factor VIIa improves clot formation but not fibrinolytic potential in patients with cirrhosis and during liver transplantation. Hepatology 2002, 35:616-621.
30. Lisman T., deGroot P.G., Meijers J.C.M., Rosendaal F.R. Reduced plasma fibrinolytic potential is a risk for venous thrombosis. Blood 2005, 105:1102-1105.
31. Martínez-Zamora M.A., Tassies D., Carmona F., Espinosa G., Cervera R., Reverter J.C., et al. Thrombin activatable fibrinolysis inhibitor (TAFI) and clot lysis time (clot lysis time) in pregnant patients with antiphospholipid syndrome (APS): relationship with pregnancy outcome and thrombosis. Am. J. Reprod. Immunol. 2009, 62:381-389.
32. Miyakis S., Lockshin M.D., Atsumi T., Branch D.W., Brey R.L., Cervera R., et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J. Thromb. Haemost. 2006, 4:295-306.
33. Morange P.E., Juhan-Vague I., Scarabin P.Y., Alessi M.C., Luc G., Arveiller D. Association between TAFI antigen and Ala 147Thr polymorphism of the TAFI gene and the angina pectoris incidence. Thromb. Haemost. 2003, 89:554-560.
34. Mousa H.A., Downey C., Alfirevic Z., Toh C. Thrombin activatable fibrinolysis inhibitor and its fibrinolytic effect in normal pregnancy. Thromb. Haemost. 2004, 92:1025-1031.
35. Roberts J.M., Cooper D.W. Pathogenesis and genetics of pre-eclampsia. Lancet 2001, 357:53-56.
36. Santamaría A., Oliver A., Borrell M., Mateo J., Belvis R., Martí-Fábregas J. Risk of ischemic stroke associated with functional thrombin-activatable fibrinolysis inhibitor plasma levels. Stroke 2003, 34:2387-2391.
37. Sartori M.T., Serena A., Saggiorato G., Campei S., Faggian D., Pagnan A. Variations in fibrinolytic parameters and inhibin-A in pregnancy: related hypertensive disorders. J. Thromb. Haemost. 2007, 6:352-358.
38. Schatteman K.A., Goosens F.J., Scharpe S.S., Hendriks D.F. Proteolytic activation of purified human procarboxypeptidase U. Clin. Chim. Acta 2000, 292:25-40.
39. Schroeder V., Kucher N., Kohler H.P. Role of thrombin activatable fibrinolysis inhibitor (TAFI) in patients with acute pulmonary embolism. J. Thromb. Haemost. 2003, 1:492-493.
40. Sucak G.T., Acar K., Sucak A., Kirazli S., Haznedar R. Increased global fibrinolytic capacity as a clue for activated fibrinolysis in pre-eclampsia. Blood Coagul. Fibrinolysis 2006, 17:347-352.
41. Van Tilburg N.H., Rosendaal F.R., Bertina R.M. Thrombin activatable fibrinolysis inhibitor and the risk for deep vein thrombosis. Blood 2000, 95:2855-2859.
42. Wang W., Boffa M.B., Bajzar L., Walker J.B., Nesheim M.E. A study of the mechanism of fibrinolysis by activated thrombin-activatable fibrinolysis inhibitor. J. Biol. Chem. 1998, 273:27176-27181.
43. Watanabe T., Minakami H., Sakata Y., Matsubara S., Sato I., Suzuki M. Changes in activity of plasma thrombin activatable fibrinolysis inhibitor in pregnancy. Gynecol. Obstet. Invest. 2004, 58:19-21.
44. Wiwanitkit V. Correlation between plasminogen activator inhibitor-1 4G/5G polymorphism and pre-eclampsia: an appraisal. Arch. Gynecol. Obstet. 2006, 273:322-324.